The polypill in the prevention of cardiovascular diseases: Key concepts, current status, challenges, and future directions

Circulation

Volumn 122, Issue 20, 2010, Pages 2078-2088

  Lonn, Eva ^a,b   Bosch, Jackie ^a   Teo, Koon K ^a,b   Pais, Prem ^c   Xavier, Denis ^c   Yusuf, Salim ^a,b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

cardiovascular diseases; drugs; prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOLIC ACID; HYDROCHLOROTHIAZIDE; LISINOPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

AGE FACTORS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 78549266131     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.873232     Document Type: Article

References (57)

1. World Health Statistics 2009. Table 2: cause-specific mortality and morbidity. Available at: http://www.who.int/whosis/whostat/EN-WHS09-Table2.pdf. Accessed July 2, 2010.
2. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
3. Ford EA, Ajani UA, Croft JB, Critchley, Ja Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decline in coronary mortality in the United States between 1980 and 2000. N Engl J Med. 2007;356: 2388-2398.
4. Luepker RV, Berger AK. Is acute myocardial infarction disappearing? Circulation. 2010;121:1280-1282.
5. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil. 2009;16:333-350.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
7. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; on behalf of the INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376: 112-123.
8. Ford ES, Li C, Zhao G, Pearson WS, Capewell S. Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. Circulation. 2009;120:1181-1188.
9. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3.
10. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-1424.
11. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med. 2005;143:593-599.
12. Wise J. Polypill holds promise for people with chronic disease. Bull World Health Organ. 2005;83:885-887.
13. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570-1577.
14. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647-658.
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
16. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ. 1981;282:1847-1851.
17. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
18. Ebrahim S, Beswick A, Burke M, Davey SG. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2006;4:CD001561.
19. Naiman A, Glazier RH, Moineddin R. Association of anti-smoking legislation with rates of hospital admission for cardiovascular and respiratory conditions. CMAJ. 2010;182:761-767.
20. Callinan JE, Clarke A, Doherty K, Kelleher C. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev. 2010 Apr 14;4: CD005992.
21. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol. 2010; 39:504-518.
22. Weinehall L, Hellsten G, Boman K, Hallmans G, Asplund K, Wall S. Can a sustainable community intervention reduce the health gap? 10-year evaluation of a Swedish community intervention program for the prevention of cardiovascular disease. Scand J Public Health Suppl. 2001; 56:59-68.
23. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-137.
24. Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, Zavodni L, Chen R, Tsang JL, Kundi A, Lin PJ, Fitchett DH, Langer A, Goodman SG; Vascular Protection Registry and Guideline Oriented Approach to Lipid Lowering Registry Investigators. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol. 2007;23:1124-1130.
25. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP; REACH Investigators. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009;8:104-111.
26. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B. WHO study on Prevention of Recurrences of Myocardial Infarction and Stroke (WHOPREMISE). Bull World Health Organ. 2005; 83:820-829.
27. Joshi R, Chow CK, Raju PK, Raju R, Reddy KS, Macmahon S, Lopez AD, Neal B. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation. 2009;119:1950-1955.
28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
29. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109: 745-749.
30. GazianoTA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679-686.
31. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bull World Health Organ. 2007;85:279-288.
32. Dudl RJ, Wang MC, Wong M, Bellows. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care. 2009;15:e88-e94.
33. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N; The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet. 2009;373:1341-1351.
34. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R; for the B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622-1631.
35. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
36. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1427.
37. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
38. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370: 1781-1790.
39. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742.
40. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-anal-ysis. Diabetes Care. 2009;32:1924-1929.
41. Law MR, Wald NJ, Moris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427-1431.
42. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
43. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923-934.
44. Yusuf S. Unresolved issues in the management of hypertension. Hypertension. 2010;55:832-834.
45. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1575-1585.
46. Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, Khamar B, Chakraborty BS. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (Polycap): a five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs. 2010;10:95-103.
47. Forslund L. Reflections on the regulation of the polypill. Nat Clin Pract Cardiovasc Med. 2009;6:94-95.
48. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006;27:1651-1656.
49. Clinical Trials Registry-India (CTRI). The Indian Polycap-K Study (TIPS-K). Available at: http://www.ctri.in/Clinicaltrials/ViewTrial.jsp?trialno= 1656. Accessed May 8, 2010.
50. Rastegarpanah M, Malekzadeh F, Thomas NG, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease: can we prevent heart attack by "heart polypill"? Arch Iranian Med. 2008;11:306-313.
51. Polypill for prevention of cardiovascular disease. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00567307?term= NCT00567307&rank=1. Accessed May 8 2010.
52. Programme to Improve Life and Longevity Pilot. Australian and New Zealand Clinical Trials Registry. Available at http://www.anzctr.org.au/trial-view. aspx?ID=1378. Accessed May 8 2010.
53. The Kanyini Guidelines Adherence with the Polypill Study. Australian and New Zealand Clinical Trials Registry. Available at http://www.anzctr.org.au/ trial-view.aspx?ID=83248. Accessed May 8 2010.
54. UMPIRE: Use of a Multidrug Pill In Reducing Cardiovascular Events. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT01057537?term=NCT01057537&rank=1. Accessed May 8 2010.
55. Sanz G, Futer V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009;6:101-110.
56. Heart Outcomes Prevention Evaluation-3 (HOPE-3). Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00468923?term= NCT00468923&rank=1. Accessed May 8, 2010.
57. Yusuf S, Pais P, Xavier D. The Indian Polycap Study (TIPS): authors' reply. Lancet. 2009;374:782.